Compare CCBG & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCBG | NGNE |
|---|---|---|
| Founded | 1895 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 828.1M | 744.9M |
| IPO Year | 1994 | 2014 |
| Metric | CCBG | NGNE |
|---|---|---|
| Price | $49.57 | $22.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $53.83 | ★ $77.63 |
| AVG Volume (30 Days) | 61.4K | ★ 261.1K |
| Earning Date | 10-20-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ 15.38 | 0.93 |
| EPS | ★ 2.86 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.18 | N/A |
| Revenue Next Year | $3.29 | N/A |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.26 | $15.93 |
| 52 Week High | $53.60 | $43.66 |
| Indicator | CCBG | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 37.26 |
| Support Level | $47.63 | $21.05 |
| Resistance Level | $51.93 | $23.35 |
| Average True Range (ATR) | 1.16 | 1.95 |
| MACD | -0.19 | -0.21 |
| Stochastic Oscillator | 19.19 | 5.99 |
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.